GBGB1516008.8A
GB201516008D0
(en)
|
2015-09-09 |
2015-09-09 |
OX40L antibodies and uses thereof
|
US14/935,937
US9434785B1
(en)
|
2015-04-30 |
2015-11-09 |
Anti-human OX40L antibodies and methods of treating graft versus host disease with the same
|
RS20230045A
RS63903B1
(en)
|
2015-03-03 |
2016-03-03 |
Antibodies, uses & methods
|
DK16715337.8T
DK3265123T3
(en)
|
2015-03-03 |
2016-03-03 |
ANTIBODIES, USES AND METHODS
|
PCT/GB2016/050565
WO2016139482A1
(en)
|
2015-03-03 |
2016-03-03 |
Antibodies, uses & methods
|
SG10201907901X
SG10201907901XA
(en)
|
2015-03-03 |
2016-03-03 |
Antibodies, uses & methods
|
DE112016001013.3T
DE112016001013T5
(en)
|
2015-03-03 |
2016-03-03 |
ANTIBODIES, USES AND METHODS
|
PT167153378T
PT3265123T
(en)
|
2015-03-03 |
2016-03-03 |
Antibodies, uses & methods
|
BR112017015880A
BR112017015880A2
(en)
|
2015-03-03 |
2016-03-03 |
antibodies, uses and methods
|
SI201631656T
SI3265123T1
(en)
|
2015-03-03 |
2016-03-03 |
Antibodies, uses & methods
|
EP22161983.6A
EP4137157A1
(en)
|
2015-03-03 |
2016-03-03 |
Antibodies, uses and methods
|
JP2017537300A
JP7094698B2
(en)
|
2015-03-03 |
2016-03-03 |
Antibodies, uses, and methods
|
PL16715337.8T
PL3265123T3
(en)
|
2015-03-03 |
2016-03-03 |
Antibodies, uses & methods
|
CN202210103864.0A
CN114504652A
(en)
|
2015-03-03 |
2016-03-03 |
Antibodies, uses and methods
|
RU2017118985A
RU2725221C2
(en)
|
2015-03-03 |
2016-03-03 |
Antibodies, their application and methods of application
|
HUE16715337A
HUE061070T2
(en)
|
2015-03-03 |
2016-03-03 |
Antibodies, uses & methods
|
CN201680008817.0A
CN108064169B
(en)
|
2015-03-03 |
2016-03-03 |
Antibodies, uses and methods
|
LTEPPCT/GB2016/050565T
LT3265123T
(en)
|
2015-03-03 |
2016-03-03 |
Antibodies, uses & methods
|
KR1020177025436A
KR20170123637A
(en)
|
2015-03-03 |
2016-03-03 |
Antibodies, Uses and Methods
|
MX2017011194A
MX2017011194A
(en)
|
2015-03-03 |
2016-03-03 |
Antibodies, uses & methods.
|
CA2968642A
CA2968642A1
(en)
|
2015-03-03 |
2016-03-03 |
Antibodies, uses & methods
|
FIEP16715337.8T
FI3265123T3
(en)
|
2015-03-03 |
2016-03-03 |
Antibodies, uses & methods
|
SG11201704160XA
SG11201704160XA
(en)
|
2015-03-03 |
2016-03-03 |
Antibodies, uses & methods
|
ES16715337T
ES2937020T3
(en)
|
2015-03-03 |
2016-03-03 |
Antibodies, uses and methods
|
CN202210103585.4A
CN114504651A
(en)
|
2015-03-03 |
2016-03-03 |
Antibodies, uses and methods
|
EP16715337.8A
EP3265123B1
(en)
|
2015-03-03 |
2016-03-03 |
Antibodies, uses & methods
|
AU2016227493A
AU2016227493B2
(en)
|
2015-03-03 |
2016-03-03 |
Antibodies, uses & methods
|
HRP20230046TT
HRP20230046T1
(en)
|
2015-03-03 |
2016-03-03 |
Antibodies, uses & methods
|
US15/142,538
US9512229B2
(en)
|
2015-03-03 |
2016-04-29 |
Synergistic combinations of OX40L antibodies for the treatment of GVHD
|
US15/333,517
US20170037137A1
(en)
|
2015-03-03 |
2016-10-25 |
Synergistic combinations of ox40l antibodies for the treatment of gvhd
|
IL252430A
IL252430A0
(en)
|
2015-03-03 |
2017-05-22 |
Antibodies, uses and methods
|
US15/604,495
US9868789B2
(en)
|
2015-03-03 |
2017-05-24 |
Synergistic combinations of OX40L antibodies for the treatment of GvHD
|
US15/661,584
US9868790B2
(en)
|
2015-03-03 |
2017-07-27 |
Synergistic combinations of OX40L antibodies for the treatment of GvHD
|
MX2023006415A
MX2023006415A
(en)
|
2015-03-03 |
2017-08-31 |
Antibodies, uses & methods.
|
MX2023006416A
MX2023006416A
(en)
|
2015-03-03 |
2017-08-31 |
Antibodies, uses & methods.
|
AU2022202539A
AU2022202539A1
(en)
|
2015-03-03 |
2022-04-19 |
Antibodies, uses & methods
|
US17/725,228
US20220372153A1
(en)
|
2015-03-03 |
2022-04-20 |
Synergistic combinations of ox40l antibodies for the treatment of gvhd
|
JP2022100443A
JP7472198B2
(en)
|
2015-03-03 |
2022-06-22 |
Antibodies, Uses, and Methods
|